[go: up one dir, main page]

AP2011005795A0 - SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia. - Google Patents

SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.

Info

Publication number
AP2011005795A0
AP2011005795A0 AP2011005795A AP2011005795A AP2011005795A0 AP 2011005795 A0 AP2011005795 A0 AP 2011005795A0 AP 2011005795 A AP2011005795 A AP 2011005795A AP 2011005795 A AP2011005795 A AP 2011005795A AP 2011005795 A0 AP2011005795 A0 AP 2011005795A0
Authority
AP
ARIPO
Prior art keywords
diabetes mellitus
type
sglt
hyperglycemia
inhibitor
Prior art date
Application number
AP2011005795A
Other languages
English (en)
Inventor
Michael Mark
Leo Thomas
Uli Broedl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2011005795(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2011005795A0 publication Critical patent/AP2011005795A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
AP2011005795A 2009-02-13 2010-02-11 SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia. AP2011005795A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15231809P 2009-02-13 2009-02-13
PCT/EP2010/051734 WO2010092123A1 (fr) 2009-02-13 2010-02-11 Inhibiteur sglt-2 pour le traitement du diabète sucré de type 1, du diabète sucré de type 2, d'une intolérance au glucose ou d'une hyperglycémie

Publications (1)

Publication Number Publication Date
AP2011005795A0 true AP2011005795A0 (en) 2011-08-31

Family

ID=42008536

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005795A AP2011005795A0 (en) 2009-02-13 2010-02-11 SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.

Country Status (28)

Country Link
US (8) US20110046087A1 (fr)
EP (1) EP2396005B1 (fr)
JP (3) JP5896276B2 (fr)
KR (2) KR20170028452A (fr)
CN (2) CN102316875A (fr)
AP (1) AP2011005795A0 (fr)
AR (1) AR075424A1 (fr)
AU (1) AU2010212865A1 (fr)
BR (1) BRPI1013640A2 (fr)
CA (1) CA2751833C (fr)
CL (1) CL2011001757A1 (fr)
CO (1) CO6410306A2 (fr)
EA (1) EA021796B1 (fr)
EC (1) ECSP11011275A (fr)
GE (1) GEP20146120B (fr)
HK (1) HK1203814A1 (fr)
IL (1) IL213723A0 (fr)
MA (1) MA33043B1 (fr)
MX (2) MX344264B (fr)
MY (1) MY161472A (fr)
NZ (1) NZ594485A (fr)
PE (1) PE20120002A1 (fr)
PH (1) PH12016501607B1 (fr)
SG (2) SG173587A1 (fr)
TN (1) TN2011000413A1 (fr)
TW (1) TWI478935B (fr)
UA (1) UA106365C2 (fr)
WO (1) WO2010092123A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1730131T3 (pl) * 2004-03-16 2012-10-31 Boehringer Ingelheim Int Glukopiranozylo-podstawione pochodne benzenu, środki lecznicze zawierające te związki, ich zastosowanie i sposób ich wytwarzania
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
BRPI0615882A2 (pt) * 2005-09-08 2011-05-31 Boehringer Ingelheim Int formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US8039441B2 (en) * 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
US8283326B2 (en) * 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20091211A1 (es) 2007-11-30 2009-09-14 Boehringer Ingelheim Int Derivados de pirazolopirimidina como moduladores de pde9a
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US8603989B2 (en) * 2008-05-22 2013-12-10 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
US9061060B2 (en) 2008-07-15 2015-06-23 Theracos Inc. Deuterated benzylbenzene derivatives and methods of use
CA2736304A1 (fr) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines et leur utilisation pour le traitement de troubles du snc
FI2395968T3 (fi) * 2009-02-13 2024-02-27 Boehringer Ingelheim Int Glukopyranosylidifenylimetaanijohdannaisia sisältävä farmaseuttinen koostumus, niiden farmaseuttinen annostusmuoto, niiden valmistusmenetelmä ja niiden käyttö potilaan glukemiasäädön parantamiseksi
PE20120017A1 (es) 2009-02-13 2012-02-12 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv, opcionalmente, un agente antidiabetico adicional, y sus usos
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
EA020798B1 (ru) 2009-09-30 2015-01-30 Бёрингер Ингельхайм Интернациональ Гмбх СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
CA2775962C (fr) 2009-09-30 2017-09-05 Boehringer Ingelheim International Gmbh Procedes de preparation de derives de benzyl-benzene substitues par un glucopyranosyle
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
MX344770B (es) 2010-08-12 2017-01-06 Boehringer Ingelheim Int Gmbh * Derivados de 6-cicloalquil-1,5-dihidro-pirazolo (3,4-d) pirimidin-4-onas y su uso como inhibidores de pde9a.
WO2012041898A1 (fr) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
PH12013502487A1 (en) * 2011-06-03 2014-01-20 Boehringer Ingelheim Int Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102627535A (zh) * 2012-03-31 2012-08-08 天津药物研究院 含1,1-二苯基环丙基结构的化合物的制备方法
EP2981269B9 (fr) * 2013-04-04 2023-12-06 Boehringer Ingelheim Vetmedica GmbH Traitement de troubles métaboliques chez des équidés
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
CA2812016A1 (fr) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
CA2812519A1 (fr) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
JP2016520564A (ja) 2013-04-18 2016-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療方法及びその使用
ES2859905T3 (es) * 2013-12-17 2021-10-04 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales felinos
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
KR20220097538A (ko) * 2014-01-23 2022-07-07 베링거잉겔하임베트메디카게엠베하 개과 동물에서 대사 장애의 치료
PL3125882T3 (pl) 2014-04-01 2020-10-19 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
WO2016036077A1 (fr) * 2014-09-02 2016-03-10 엘지전자 주식회사 Appareil de réception de diffusion générale, procédé d'exploitation d'un appareil de réception de diffusion générale, appareil imbriqué s'imbriquant avec un appareil de réception de diffusion générale, et procédé d'exploitation d'un appareil imbriqué
DK3197429T3 (da) 2014-09-25 2024-08-26 Boehringer Ingelheim Vetmedica Gmbh Kombinationsbehandling med sglt2-hæmmere og dopaminagonister til forebyggelse af metaboliske lidelser af dyr i hestefamilien
WO2016174155A1 (fr) * 2015-04-30 2016-11-03 Boehringer Ingelheim International Gmbh Procédés et compositions pharmaceutiques comprenant un inhibiteur de sglt2 pour le traitement ou l'amélioration d'une dysérection
WO2016210008A1 (fr) * 2015-06-22 2016-12-29 Berg Llc Compositions comprenant de l'eno1 et leur utilisation dans des procédés de traitement de l'obésité ou de la surcharge pondérale et de réduction de la prise de poids
HUE069575T2 (hu) 2015-08-27 2025-03-28 Boehringer Ingelheim Vetmedica Gmbh Folyékony gyógyászati készítmények, amelyek SGLT-2-inhibitorokat tartalmaznak
EP3362055B1 (fr) 2015-10-15 2023-01-18 Boehringer Ingelheim International GmbH Inhibiteur de sglt-2 destiné à être utilisé dans le traitement d'une myopathie métabolique
MX2019005435A (es) 2016-11-10 2019-07-10 Boehringer Ingelheim Int Composicion farmaceutica, metodos para tratamiento y sus usos.
WO2019087239A1 (fr) * 2017-10-30 2019-05-09 合同会社カルナヘルスサポート Agent thérapeutique contre la néphropathie
AU2019254371A1 (en) * 2018-04-17 2020-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR102408480B1 (ko) 2018-05-30 2022-06-10 이삼구 당뇨질환의 치료용 조성물
CN110141555A (zh) * 2019-06-21 2019-08-20 江苏豪森药业集团有限公司 一种恩格列净片及其制备方法
CN118615450A (zh) * 2020-02-17 2024-09-10 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
US20220016078A1 (en) * 2020-07-14 2022-01-20 GyanRx Sciences, Inc. Methods Of Treating Kidney Stones
KR20230112426A (ko) * 2022-01-20 2023-07-27 주식회사 대웅제약 이나보글리플로진을 포함하는 개과 동물의 비만 예방 또는 치료용 약학 조성물
CN119968202A (zh) * 2022-09-29 2025-05-09 株式会社大熊制药 用于预防或治疗心血管衰老疾病的包含依那格列净的药物组合物
WO2024116198A1 (fr) * 2022-12-02 2024-06-06 Syri Research Private Limited Formulation liquide orale d'empagliflozine ou de son sel pharmaceutiquement acceptable

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
CA2444481A1 (fr) * 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Complexes acides amines de glucocides c-aryle pour le traitement du diabete et procede correspondant
PL1730131T3 (pl) * 2004-03-16 2012-10-31 Boehringer Ingelheim Int Glukopiranozylo-podstawione pochodne benzenu, środki lecznicze zawierające te związki, ich zastosowanie i sposób ich wytwarzania
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
EP1828216B1 (fr) * 2004-12-16 2008-09-10 Boehringer Ingelheim International GmbH Derives de benzene substitues par glucopyranosyle, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
JP5264183B2 (ja) * 2005-02-23 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
DE602006011453D1 (de) * 2005-04-15 2010-02-11 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte (heteroaryloxy-benzyl)-benzen-derivate als sglt-inhibitoren
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EP1910390B1 (fr) * 2005-07-27 2010-05-19 Boehringer Ingelheim International GmbH Derives de ((hetero)cycloalkylethynyl-benzyl)-benzene glucopyranosyl-substitutes, medicaments contenant ces composes, leur utilisation, et procede pour les produire
ATE484499T1 (de) * 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
BRPI0615882A2 (pt) 2005-09-08 2011-05-31 Boehringer Ingelheim Int formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
ATE517099T1 (de) * 2006-02-15 2011-08-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
BRPI0711949A2 (pt) * 2006-05-19 2012-01-17 Taisho Pharmaceutical Co., Ltd. composto c-fenil glicitol
US8039441B2 (en) 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
US8283326B2 (en) 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
AR063569A1 (es) 2006-11-06 2009-02-04 Boehringer Ingelheim Int Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
AR063627A1 (es) 2006-11-09 2009-02-04 Boehringer Ingelheim Int Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20120017A1 (es) * 2009-02-13 2012-02-12 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv, opcionalmente, un agente antidiabetico adicional, y sus usos
US9192617B2 (en) * 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) * 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
ES2702174T3 (es) * 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina

Also Published As

Publication number Publication date
EP2396005B1 (fr) 2025-11-26
PH12016501607A1 (en) 2017-10-18
TW201040194A (en) 2010-11-16
PE20120002A1 (es) 2012-02-12
BRPI1013640A2 (pt) 2019-09-24
CO6410306A2 (es) 2012-03-30
CL2011001757A1 (es) 2011-10-28
MA33043B1 (fr) 2012-02-01
MY161472A (en) 2017-04-14
MX344264B (es) 2016-12-09
EA021796B1 (ru) 2015-09-30
NZ594485A (en) 2013-07-26
US20170020907A1 (en) 2017-01-26
US20140031301A1 (en) 2014-01-30
CA2751833A1 (fr) 2010-08-19
WO2010092123A1 (fr) 2010-08-19
CN104138370A (zh) 2014-11-12
CN102316875A (zh) 2012-01-11
AR075424A1 (es) 2011-03-30
KR20170028452A (ko) 2017-03-13
US20160158264A1 (en) 2016-06-09
GEP20146120B (en) 2014-07-25
ECSP11011275A (es) 2011-09-30
JP2017052787A (ja) 2017-03-16
US20120196812A1 (en) 2012-08-02
HK1203814A1 (en) 2015-11-06
TN2011000413A1 (en) 2013-03-27
US20220313716A1 (en) 2022-10-06
WO2010092123A8 (fr) 2011-06-30
US20110046087A1 (en) 2011-02-24
CA2751833C (fr) 2018-11-06
JP2015042691A (ja) 2015-03-05
IL213723A0 (en) 2011-07-31
JP5896276B2 (ja) 2016-03-30
EP2396005A1 (fr) 2011-12-21
US20200069713A1 (en) 2020-03-05
KR20110118668A (ko) 2011-10-31
AU2010212865A1 (en) 2011-07-21
JP2012517975A (ja) 2012-08-09
MX2011008214A (es) 2011-11-29
MX387010B (es) 2025-03-19
SG10201600204YA (en) 2016-02-26
AU2010212865A8 (en) 2011-11-17
EA201101189A1 (ru) 2012-03-30
SG173587A1 (en) 2011-09-29
PH12016501607B1 (en) 2024-02-21
UA106365C2 (ru) 2014-08-26
US20210283156A1 (en) 2021-09-16
TWI478935B (zh) 2015-04-01

Similar Documents

Publication Publication Date Title
AP2011005795A0 (en) SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.
ZA200900501B (en) Combination treatment for diabetes mellitus
IL212559A0 (en) Oxidatitive photoactivated skin rejuvenation composition comprising hyaluronic acid, glucosamine. or allatoin
EP2787345B8 (fr) Options de traitement pour la maladie de fabry
WO2010008739A3 (fr) Agonistes des récepteurs gpr119 aryles et utilisations associées
AP2011005754A0 (en) Processing biomas.
SI2334687T1 (sl) Dioksa biciklo oktan triol derivati
AP2012006281A0 (en) Dioxa-bicycloÄ3.2.1Üoctane-2,3,4-triol derivatives.
ZA200706294B (en) Roflumilast for the treatment of diabetes mellitus
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
BR112012000840A2 (pt) método para produzir uma solução de açucar, e dispositivo de sacarificação.
EG25048A (en) Roller device, particularly push roller frame.
PL2441462T3 (pl) Sposób leczenia cukrzycy typu I
GB2435025B (en) Pusher mechanism for i.s.machine
PT1934252E (pt) Processo para a preparação de conjugados de insulina
GB2431925B (en) Pushout mechanism for I.S. machine
GB2470515A8 (en) Improvements relating to optical printers.
GB0625182D0 (en) Supplementary patent to 0624018.8 Claims 1a,2,3,4 & 5
杨品文 She wins You win
王春宏 et al. 西藏崩纳藏布砂金矿中金的来源研究
HU0600567D0 (en) Process for producing of functional pasta with low carbohydrate, especially nutrition of diabetes
王怀超 et al. 青海省智益 铜峪沟华力西期铜, 铅, 锌, 锡成矿亚带
PL381198A1 (pl) Suplement diety, zwłaszcza dla diabetyków
魏冠军 et al. 澜沧老厂多源地学数据融合分析
段晓华 甘肃马泉金矿成因类型探讨